09.22.25 -- How AbbVie's Digital Transformation Brought Platform Knowledge Closer

As you develop your future cell therapy drug, consider the risks and benefits of using autologous or allogeneic methods to best suit your development and manufacturing needs.

In a collaborative outsourcing model, the sponsor maintains direct contact with functional leads, eliminating communication gaps and enabling faster, better-informed decision-making.

This study compared non-viral transfection methods in primary human T-cells, demonstrating the feasibility of an LNP-based process encapsulating CRISPR/Cas9 and HDR template DNA in a single payload.

Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based and biochemical assays, and more.

Discover a bispecific pairing technology that drives correct heavy-light chain pairing rates in IgG-like bispecifics to >95%. This improves yields of the correct species and streamlines downstream processing.

Founder and CEO Ruby Tsai, Ph.D., delves into the general methodologies for reducing immunogenicity in cell-based therapeutics and highlights the unique approach employed to overcome immune rejection challenges.

While clinical efficacy is the critical benchmark for any drug program, ensuring manufacturability is also vital. An experienced CDMO can help you establish efficient and cost-effective production strategies.

Consider an advanced sequencing protocols and bioinformatics solutions to achieve comprehensive rAAV characterization, ensuring precise analysis of purity, integrity, and identity.

Streamlining the tech transfer process is a key variable in shortening development timelines and controlling costs, maximizing a molecule's potential for late-stage success.